Analysis of Mortality, Gravity Predictive Factors and Evolution of Clinical Characteristics of Older Patients Hospitalized for COVID-19 in Short Geriatric Services.
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 450
- Locations
- 5
- Primary Endpoint
- In hospital mortality rate.
Study Overview
Brief Summary
Since the beginning of the year 2020, clinical characteristics of a new disease as the global COVID-19 epidemic has spread in France. People over 70 years of age are the more concerned by this virus in proportion and in gravity with some atypical first symptoms compared to younger patients. Evolution of the disease is variable from forms with few symptoms to severe forms sometimes quickly lethal.
GERICOVID LYON is a descriptive analysis of all patients over 70 years of age hospitalised for COVID-19 in short geriatric unities of University Hospital of Lyon This study will allow more comprehension about COVID-19 in older people. The role of predictive factors, pre-existing comorbidities and the nature and frequency of complications in a short period will be investigate. Treatments practices will be analysed too.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 70 Years to — (Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient over 70 years of age.
- •Patient hospitalized in short geriatric units in University Hospital of Lyon.
- •Patient diagnosed with COVID-19 (positive Polymerase Chain Reaction or a high presumption of COVID-19 based on clinical and/or scannographic evidence).
- •Patient Informed and non-opposed to the research (Patient informed of the study by his medical doctor during hospitalization or by post, thanks to a generic information sheet dedicated to COVID-19 researches).
Exclusion Criteria
- •Patient opposed to the research.
Outcomes
Primary Outcomes
In hospital mortality rate.
Time Frame: During patient hospitalization, an average of 10 days.
Observed mortality rate will be presented with its 95% confidence interval.
Secondary Outcomes
No secondary outcomes reported